Health ❯ Healthcare ❯ Clinical Trials ❯ Drug Development

FDA Approval

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension

The agency requested additional evidence of effectiveness to support a favorable benefit–risk assessment.